How should kidney function be monitored during Cladribine therapy?

CBC with differential (profound, prolonged myelosuppression and CD4 lymphopenia); Creatinine/eGFR and tumor-lysis panel in high-burden disease; Infection surveillance (opportunistic infections); Neurologic exam at higher doses.

How can kidney injury from Cladribine be prevented?

Tumor-lysis prophylaxis by risk: IV hydration plus allopurinol (intermediate) or rasburicase (high) PJP and herpesvirus prophylaxis for prolonged CD4 lymphopenia Reduce/space the dose in significant CKD rather than withholding

Who is at higher risk of kidney injury from Cladribine?

High tumor burden/leukocytosis and bulky disease; Pre-existing renal impairment and volume depletion; High cumulative or high-dose regimens; High baseline uric acid.

Back to explorer

Printable monograph

Purine analog

Cladribine

Leustatin · CLAD

Purine analog · approved 1993 · 10 citations

Recent· through 2023

Deeply sourced7/9 · 6 signals

Met: 10 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 38y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2023
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A purine analog that is renally quiet at standard hairy-cell doses — its kidney risk is tumor lysis, not the drug.

MildPurine nucleoside analog

Hairy-cell leukemiaOff-label: chronic lymphocytic leukemia, low-grade non-Hodgkin lymphoma, Langerhans-cell histiocytosis, AML regimens (CLAG)

§01

Signature kidney injury

Signature lesion

Crystal / Obstructive Nephropathy

At standard hairy-cell-leukemia doses cladribine is renally quiet; clinically significant nephrotoxicity is uncommon and dose-related, worst at historical high investigational doses. The dominant renal hazard is tumor lysis syndrome in bulky/leukocytotic disease, reported at the case level rather than as a population incidence.Source: Saven et al., Blood 1998

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Tumor-lysis AKI is acute, within 24–72 h.

Distilled from: “Tumor-lysis AKI is acute (24-72 h); high-dose sensorimotor neuropathy is delayed (weeks).”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Crystal / Obstructive Nephropathy#1 · Signaturequalitative — no citable incidence
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityMild

ReversibilityReversible

Evidence10 citations

Nephron map

Vasculature / Endothelium

Distal Tubule / Collecting Duct

Tubular LumenThe urine flow path

Crystal / Obstructive Nephropathy

Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.

§03

Kidney injury

Mechanism of kidney injury

Renal injury is largely indirect: rapid lysis of bulky disease causes tumor lysis syndrome with hyperuricemia (urate crystal nephropathy and intratubular obstruction), hyperphosphatemia (calcium-phosphate deposition) and hyperkalemia, producing crystal/obstructive and hemodynamic AKI. Cladribine is not a direct tubular toxin at standard doses; a dose-related intrinsic nephrotoxicity emerges only with the high doses used historically.

Clinical presentation

When tumor lysis occurs: a rising uric acid, phosphate and potassium with a falling calcium and rising creatinine within 24-72 h of starting therapy in high-burden disease. Profound and prolonged CD4 lymphopenia follows treatment (opportunistic-infection risk).

Management

Standard tumor-lysis management: aggressive hydration, rasburicase for hyperuricemia (avoid urinary alkalinization with rasburicase), correct electrolytes, and dialysis for refractory derangements. Supportive care for myelosuppression and infection surveillance.Lesion-level management framework

Risk factors

High tumor burden/leukocytosis and bulky disease
Pre-existing renal impairment and volume depletion
High cumulative or high-dose regimens
High baseline uric acid

Prevention

Tumor-lysis prophylaxis by risk: IV hydration plus allopurinol (intermediate) or rasburicase (high)
PJP and herpesvirus prophylaxis for prolonged CD4 lymphopenia
Reduce/space the dose in significant CKD rather than withholding

Anticancer mechanism· how it treats cancer

Purine nucleoside analog of deoxyadenosine; the 2-chloro substitution resists adenosine deaminase. Phosphorylated by deoxycytidine kinase to 2-chloro-dATP, which accumulates selectively in lymphocytes and monocytes (high deoxycytidine kinase, low 5'-nucleotidase), causing DNA strand breaks, NAD/ATP depletion and apoptosis of both dividing and resting cells.

Note · Established (1993) agent; renal events are tumor-lysis-driven and case-level, not population-quantified. Direct nephrotoxicity is a high-dose phenomenon.

§04

Clinical depth

Renal dose adjustment

Substantially renally eliminated; the label advises caution and consideration of dose reduction with close monitoring in renal impairment. No firmly validated CrCl bands exist; published practice uses reduced/spaced (e.g. every-other-week) dosing in severe CKD, where complete remission is still achievable.

Dialyzability & ESKD dosing

Not reliably characterized and not considered readily dialyzable for drug removal; dialysis is used to manage tumor-lysis metabolic derangements.

Differential diagnosis

Tumor lysis (most likely with bulky disease) versus prerenal volume depletion, neutropenic-sepsis ATN, concurrent nephrotoxins and disease infiltration/CKD. The metabolic panel and tumor burden anchor the diagnosis.

Monitoring

CBC with differential (profound, prolonged myelosuppression and CD4 lymphopenia)
Creatinine/eGFR and tumor-lysis panel in high-burden disease
Infection surveillance (opportunistic infections)
Neurologic exam at higher doses

Key trials & series

Scripps long-term HCL cohort (Saven, Blood 1998) — 91% CR, standard of care
Dann NEJM 1993 — classic case linking cladribine to tumor lysis syndrome

Clinical pearls

At standard hairy-cell doses cladribine is renally quiet — the dominant risk is tumor lysis, which scales with tumor burden, not drug exposure.
Reduce/space the dose and monitor in CKD rather than withholding — complete remission is achievable even in severe renal failure.
The feared high-dose toxicity is delayed, potentially irreversible sensorimotor neuropathy.
Profound durable CD4 lymphopenia is the rule — plan opportunistic-infection prophylaxis.

Beyond the kidney — non-renal toxicities· 4 organ systems

Class-level context for the major non-renal toxicities of the Purine analog class.

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Mucositis and diarrhea

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

Transaminitis (methotrexate)

Hematologic

Cytopenias, thrombosis, TMA

Myelosuppression

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Methotrexate / gemcitabine pneumonitis

§05

References

8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

8 references · 1985–2023 · 1 since 2021

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 2

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedAutoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.Schönfelder K et al. · Mult Scler 2021 · PMID 34165361Anti-glomerular basement membrane antibody-mediated glomerulonephritis arising shortly after a cladribine treatment cycle, reported as cladribine-associated secondary autoimmune kidney injury.CaseC · LimitedPharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure.Crews KR et al. · J Pediatr Hematol Oncol 2002 · PMID 12439044Child who developed acute renal failure during cladribine (2-CdA) plus cytarabine therapy, with reduced drug clearance requiring hemofiltration/hemodialysis.

FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Dec 2025) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING Cladribine injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received cladribine injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of cladribine (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/therapies.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 9,555 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 2 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Crystal / Obstructive Nephropathycorroborated · ROR 2.77
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Electrolyte DisturbanceNo disproportionate reporting — This phenotype IS reportable and this agent has enough reports, yet the reporting is not disproportionate — the one genuinely informative negative of the four.

Crystal / Obstructive Nephropathy

ROR 2.7795% CI 2.19–3.51· 70 reports

Hemorrhagic Cystitis

ROR 1.3695% CI 1.01–1.84· 43 reports

FAERS outcomes & reporting trend· 7.4% of reports w/ death · 23.2% w/ hospitalization

7.4%

Reported with a death outcome

709 of 9,555 reports

23.2%

Reported with hospitalization

2,213 of 9,555 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 6 systems · 9,555 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 0.5295% CI 0.37–0.72· 36 AKI reports ·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.

Renal & urinary

Urinary Tract Infection280

General / constitutional

Fatigue814Pyrexia287Asthenia244Pain196Fall191

Blood & lymphatic

White Blood Cell Count Decreased363Lymphopenia230Febrile Neutropenia215Neutropenia173Pancytopenia164

Immune / infection

Pneumonia406Covid-19201Sepsis173Lower Respiratory Tract Infection165

Nervous system

Headache681Dizziness187

Gastrointestinal

Nausea423Diarrhoea206Vomiting161

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ADQIConventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupKidney Int 2026 · PMID 41881107Cisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Cladribine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Hydroxyurea

Hydrea · Ribonucleotide reductase inhibitor

Profile

Tumor lysis in myeloproliferative disease.

XTALPRELYTE

Mild#1 · 100% phenotype match

Nelarabine

Arranon · Purine analog

Profile

Tumor lysis in T-ALL.

XTALPRELYTE

Mild#2 · 100% phenotype match

Fludarabine

Fludara · Purine analog

Profile

Tumor lysis; accumulates in renal impairment.

XTALPRELYTE

Moderate#3 · 94% phenotype match

Etoposide

Etopophos · Topoisomerase II inhibitor

Profile

Tumor lysis; renally cleared.

XTALPRELYTE

Mild#4 · 89% phenotype match

Pomalidomide

Pomalyst · Immunomodulatory drug (IMiD)

Profile

Tumor lysis; usable in renal impairment.

PRELYTEXTAL

Mild#5 · 89% phenotype match

Thalidomide

Thalomid · Immunomodulatory drug (IMiD)

Profile

Tumor lysis and bradycardia.

PRELYTEXTAL

Mild#6 · 89% phenotype match

Compare Cladribine with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Antimetabolites

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.